Editing of haemoglobin genes
AssigneeOxford University Innovation Limited
InventorsJames DAVIES, Douglas HIGGS, Mohsin BADAT
Life of this patent
Estimating the term…
Loading patent…
AssigneeOxford University Innovation Limited
InventorsJames DAVIES, Douglas HIGGS, Mohsin BADAT
Estimating the term…
The present invention relates to a process for producing a modified nucleic acid, wherein the nucleic acid comprises a mutant haemoglobin B (HBB) gene encoding a mutant Hb-β polypeptide. The process comprises using a base editor, preferably with a gRNA, to edit the mutant HBB gene to change a first (mutant) codon in that gene into a second, non-wild-type codon, wherein the Hb-β polypeptide encoded by that edited HBB gene has a non-wild-type, yet phenotypically-viable, amino acid sequence. The invention also provides a population of isolated haematopoietic stem cells, the stem cells comprising edited HBB genes.
A process for producing a modified nucleic acid molecule, the process comprising the steps:
The process as claimed in wherein the base editor is a programmable nucleic acid binding protein (or an impaired CRISPR-Cas9 mutant, which is capable of being targeted to a target DNA sequence.
The process as claimed in wherein the edited HBB gene consists of or comprises:
A population of isolated cells comprising haematopoietic stem cells or progenitor cells comprising edited HBB genes, the edited HBB genes comprising:
Dependencies are inferred from the claim text.